Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma.
Andrew L LinViviane TabarRobert J YoungEliza B GeerPublished in: Pituitary (2023)
Patients with a suspected papillary craniopharyngioma can be challenged with dabrafenib as a potentially effective diagnostic and therapeutic strategy, given that rapid regression with dabrafenib is only observed in tumors harboring a BRAF V600 mutation. Further work is needed to explore the optimal regimen and dose of the targeted therapy.